<DOC>
	<DOCNO>NCT00496769</DOCNO>
	<brief_summary>The purpose clinical research study determine whether apixaban effective acetylsalicylic acid prevention stroke associate patient atrial fibrillation . The safety treatment also study .</brief_summary>
	<brief_title>A Phase III Study Apixaban Patients With Atrial Fibrillation</brief_title>
	<detailed_description>An optional Long-term Open-label Extension Phase treatment apixaban provide qualify participant follow conclusion double-blind phase</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Key Male female Age 50 year old Permanent , paroxysmal , persistent atrial fibrillation ( screen within 6 month prior enrollment ) document 12lead electrocardiogram ) At least 1 follow risk factor stroke : Prior stroke transient ischemic attack Age 75 year old Arterial hypertension treatment Diabetes mellitus Heart failure ( New York Health Authority Class 2 great time enrollment ) Left ventricular ejection fraction 35 % less , document within 6 month enrollment Peripheral arterial disease ( previous arterial revascularization , limb foot amputation , current intermittent claudication anklearm systolic blood pressure ratio &lt; 0.9 ) Not currently receive vitamin K antagonist therapy 1 follow reason : Previous vitamin K antagonist therapy demonstrate unsuitable discontinue Vitamin K antagonist therapy previously use expect unsuitable Key Women pregnant breast feed Women child bear potential unwilling meet study requirement pregnancy test unwilling unable use acceptable method avoid pregnancy Atrial fibrillation due reversible cause , thyrotoxicosis pericarditis Valvular disease require surgery Planned ablation procedure atrial fibrillation perform within 3 month Conditions atrial fibrillation require chronic anticoagulation ( , prosthetic mechanical heart valve , venous thromboembolism ) Patients serious bleed last 6 month high risk bleeding , include limited : Active peptic ulcer disease Platelet count &lt; 100,000/mm^3 hemoglobin &lt; 10g/dL Recent stroke ( within 10 day ) Documented hemorrhagic tendency blood dyscrasias Current alcohol drug abuse psychosocial reason make study participation impractical Severe comorbid condition life expectancy &lt; 1 year Severe renal insufficiency ; patient serum creatinine level &gt; 2.5 mg/dL calculate creatinine clearance &lt; 25 mL/min exclude Alanine transaminase aspartate aminotransferase level &gt; 2 time upper limit normal ( ULN ) total bilirubin level &gt; 1.5 time ULN ( unless alternative causative factor [ Gilbert 's syndrome ] identify ) Allergy adverse reaction acetylsalicylic acid Required treatment thienopyridine ( clopidogrel ticlopidine ) Prisoners participant compulsory detain ( involuntarily incarcerate ) Use investigational drug device within past 30 day prior randomization apixaban clinical study Patients compulsorily detain treatment psychiatric physical illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>